Kazia Says It Evaluates Next Steps In NDU Glioblastoma; Believes Paxalisib Shows Potential To Be Evaluated In Breast Cancers
Kazia Says It Evaluates Next Steps In NDU Glioblastoma; Believes Paxalisib Shows Potential To Be Evaluated In Breast Cancers
Kazia表示正在评估NDU胶质母细胞瘤的下一步；认为Paxalisib在乳腺癌中显示出潜力。
"We recently presented very exciting data at the San Antonio Breast Cancer meeting highlighting synergistic activity between a novel combination of paxalisib and immunotherapy, and we believe paxalisib shows potential to be evaluated in breast cancers where iPI3K pathway mutations are known to drive tumor growth. The Kazia team, in conjunction with the Board of Directors, is continuing to evaluate several options, and we expect to provide an outline for our path forward to maximize shareholder value by the end of January 2025," the company said.
“我们最近在圣安东尼奥乳腺癌会议上展示了一些非常令人兴奋的数据，强调了一种新型的paxalisib与免疫疗法的联合使用之间的协同作用，我们相信paxalisib在已知驱动肿瘤生长的iPI0.3万通路突变的乳腺癌患者中具有潜在的评估价值。Kazia团队与董事会共同继续评估几个期权，我们预计将在2025年1月底之前提供一个概述，以最大化股东价值，”公司表示。